

CHOKRI

UNITED STATES DEPARTMENT OF COMMERCE

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

		<i>\</i> γβ	
FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.	

HM12/0915 TEXAMINER

YOUNG & THOMPSON

745 SOUTH 23RD STREET

SECOND FLOOR

ARLINGTON VA 22202

HM12/0915 TEXAMINER

VANDER VEGT, F

ARTUNIT PAPER NUMBER

1644

DATE MAILED:

09/15/99

USB96AKIDM

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

APPLICATION NO.

097194, 053

FILING DATE

Office Action Summary

Application No.

Applicant(s)

09/194,053

Chokri et al

Examiner

F. Pierre VanderVegt

Group Art Unit 1644



X Responsive to communication(s) filed on Jun 17, 1999	
☐ This action is FINAL .	•
☐ Since this application is in condition for allowance except for formal in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D.	al matters, prosecution as to the merits is closed 11; 453 O.G. 213.
A shortened statutory period for response to this action is set to expir is longer, from the mailing date of this communication. Failure to respapplication to become abandoned. (35 U.S.C. § 133). Extensions of 37 CFR 1.136(a).	re <u>one</u> month(s), or thirty days, whichever
Disposition of Claims	
	jø/are pending in the application.
Of the above, claim(s)	
Claim(s)	is/are ellewed
☐ Claim(s)	is/are rainched.
☐ Claim(s)	is/are rejected.
	Is/are objected to.
	sie subject to restriction or election requirement.
Application Papers	
☐ See the attached Notice of Draftsperson's Patent Drawing Revie	·
The drawing(s) filed on is/are objected to b	
The proposed drawing correction, filed on	is 🗔 approved 🗔 disapproved.
The specification is objected to by the Examiner.	
☐ The oath or declaration is objected to by the Examiner.	
Priority under 35 U.S.C. § 119	
Acknowledgement is made of a claim for foreign priority under 3	35 U.S.C. § 119(a)-(d):
☐ All ☐ Some* ☐ None of the CERTIFIED copies of the pr☐ received.	iority documents have been
 received in Application No. (Series Code/Serial Number) received in this national stage application from the International 	tional D (DOT D.)
*Certified copies not received:	tional Bureau (PC1 Rule 17.2(a)).
☐ Acknowledgement is made of a claim for domestic priority under	r 35 U.S.C. § 119(e)
Attachment(s)	. 55 515.5. 3 1 15(6).
☐ Notice of References Cited, PTO-892	
☐ Information Disclosure Statement(s), PTO-1449, Paper No(s)	·
☐ Interview Summary, PTO-413	
Notice of Draftsperson's Patent Drawing Review, PTO-948	
□ Notice of Informal Patent Application, PTO-152	
SEE OFFICE ACTION ON THE FOLL	101///10 24 27

Application/Control Number: 09/194,053 Page 2

Art Unit: 1644

DETAILED ACTION

This application is a rule 371 continuation of PCT/EP97/02703.

Claims 1-43 have been canceled.

New claims 44-85 have been added and are currently pending in this application..

5

10

15

reduce processing time, Group 1640 is running a Fax Response Pilot for Written Restriction Requirements. A dedicated Fax machine is in place to receive your responses. The Fax number is 703-305-3704. A Fax cover sheet is attached to this Office Action for your convenience. We encourage your participation in this Pilot program. If you have any questions or suggestions please contact Paula Hutzell, Supervisory Patent Examiner at Paula. Hutzell@uspto.gov or 703-308-4310. Thank you in advance for allowing us to enhance our customer service. Please limit the use of this dedicated Fax number to responses to Written

Please Note: In an effort to enhance communication with our customers and

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

Restrictions.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, Applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

25

20

Group I, claim(s) 44-66 and 75-76 and 80-81, drawn to monocyte-derived antigen presenting cells.

Group II, claim(s) 67-74 and 85, drawn to a process for preparing a composition comprising monocyte-derived antigen presenting cells.

30

Group III, claim(s) 77, drawn to a histamine or cimetidine containing medium for the growth of monocyte-derived antigen presenting cells.

Art Unit: 1644

5

10

15

20

25

Group IV, claim(s) 78-79, drawn to a cell processor kit.

Group V, claim(s) 82-84, drawn to a method of cell therapy comprising monocyte-derived antigen presenting cells.

The inventions listed as Groups I-V do not relate to a single general inventive concept 2. under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Group I is drawn to a monocyte-derived antigen presenting cell of a specific phenotype and Group II most broadly claims a process for the preparation of monocyte-derived antigen presenting cells using chemical ligands of mononuclear cells. However, the process is not limited to the production of monocyte-derived antigen presenting cells of the phenotype claimed in Group I and the method encompasses the preparation of monocyte-derived antigen presenting cells which are distinct from those of Group I. Further, the method of cell therapy of Group V comprises the use of cells limited only by their ability to be made by the broadest claimed method of Group II and, therefore encompasses the use of antigen presenting cells distinct from those of Group I. The groups therefore lack a common special technical feature of the monocyte-derived antigen presenting cells of the phenotype of Group I because other Groups are not limited to cells of that specific phenotype.

A telephone call was made to Roland Long on September 2, 1999 to request an oral 3. election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the 4. inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any

Application/Control Number: 09/194,053

Art Unit: 1644

Page 4

amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

Papers related to this application may be submitted to Technology Center 1600, Group 1640 by facsimile transmission. Papers should be faxed to Group 1640 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The fax phone number for official documents to be entered into the record for Art Unit 1644 is (703)305-3014.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to F. Pierre VanderVegt, whose telephone number is (703)305-6997. The Examiner can normally be reached Tuesday through Friday and even-numbered Mondays (on 1999 365-day calender) from 7:00 am to 4:00 pm ET. A message may be left on the Examiner's voice mail service. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Ms. Christina Chan can be reached at (703)308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist, whose telephone number is (703)308-0196.

20

5

10

15

F. Pierre VanderVegt, Ph.D.

Patent Examiner

Technology Center 1600

25 September 13, 1999